Monitor future 8-K filings for actual equity grant details under the new plan. The approval is routine and does not change the company's near-term outlook.
Price Chart
Executive Summary
United Therapeutics shareholders approved the 2026 Stock Incentive Plan at the annual meeting, adding 1,500,000 new shares plus the remaining 2,413,730 shares from the prior plan to the equity compensation reserve. All 12 director nominees were elected, and the advisory say-on-pay resolution passed with 97% support. This is a routine governance filing with no material financial impact.
Key Facts
- Shareholders approved the 2026 Stock Incentive Plan with 25,872,075 votes for and 10,070,290 against (72% of votes cast in favor).
- The plan adds 1,500,000 new shares plus 2,413,730 shares remaining from the prior plan, with potential additional shares from forfeited awards.
- All 12 director nominees were elected with strong support (lowest 'for' vote was 32,342,983 for Christopher Causey).
- Advisory vote on executive compensation passed with 35,152,059 votes for (97% of votes cast).
- Ernst & Young LLP was ratified as independent auditor for 2026 with 35,753,887 votes for.
Financial Impact
No immediate financial impact; the plan authorizes future equity grants but no specific grants were made in this filing.
Risk Factors
- Potential future dilution from equity grants under the new plan, though the 1,500,000 new shares represent approximately 3% of outstanding shares.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-078865 |
| Document: tm2619258d1_8k.htm | 0001104659-26-078865 |
| Document: 0001104659-26-078865-index-headers.html | 0001104659-26-078865 |
| Document: 0001104659-26-078865-index.html | 0001104659-26-078865 |
| Document: 0001104659-26-078865.txt | 0001104659-26-078865 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $500.35 $497.31 | ▼ −0.61% | ▼ −2.72% | $571.38 (+14.20%) |
Sep 11, 2026 21d ago | Insider Cluster | $497.11 $494.63 | ▼ −0.50% | ▼ −0.28% | $571.38 (+14.94%) |
Sep 10, 2026 22d ago | Insider Cluster | $503.86 $497.27 | ▼ −1.31% | ▼ −0.81% | $571.38 (+13.40%) |
Sep 9, 2026 23d ago | Insider Cluster | $506.82 $498.48 | ▼ −1.65% | ▼ −0.99% | $571.38 (+12.74%) |
Sep 4, 2026 28d ago | Insider Cluster | $487.61 $502.70 | ▲ +3.09% | ▲ +4.30% | $571.38 (+17.18%) |
Sep 3, 2026 29d ago | Insider Cluster | $488.16 $497.11 | ▲ +1.83% | ▲ +2.98% | $571.38 (+17.05%) |
Aug 28, 2026 5w ago | Insider Cluster | $515.46 $487.61 | ▼ −5.40% | ▼ −5.51% | $571.38 (+10.85%) |
Aug 27, 2026 5w ago | Insider Cluster | $527.91 $492.02 | ▼ −6.80% | ▼ −6.03% | $571.38 (+8.23%) |
Aug 26, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $571.38 (+10.59%) |
Aug 25, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $571.38 (+10.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access